MARKET

OMER

OMER

Omeros
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.98
+0.10
+0.67%
Closed 16:14 06/01 EDT
OPEN
14.72
PREV CLOSE
14.88
HIGH
15.25
LOW
14.51
VOLUME
291.44K
TURNOVER
--
52 WEEK HIGH
20.92
52 WEEK LOW
8.50
MARKET CAP
816.57M
P/E (TTM)
-8.6102
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average OMER stock price target is 35.40 with a high estimate of 75.00 and a low estimate of 17.00.

EPS

OMER News

More
Edited Transcript of OMER earnings conference call or presentation 11-May-20 8:30pm GMT
Q1 2020 Omeros Corp Earnings Call
Thomson Reuters StreetEvents · 5d ago
Omeros Gets Technical Rating Upgrade, Relative Strength Line Moves Up To 75
Investor's Business Daily · 6d ago
Omeros: Some Concerns Remain... As Do Opportunities
Seeking Alpha - Article · 05/14 14:05
Omeros To Present Narsoplimab Pivotal Trial Data At European Hematology Association Annual Congress Jun. 11-14
Omeros Corporation (NASDAQ:OMER) today announced that the results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy will be presented at the
Benzinga · 05/14 13:07
Omeros Corporation Announces Presentation of Narsoplimab Pivotal Trial Data at Upcoming European Hematology Association Annual Congress
Omeros Corporation (Nasdaq: OMER) today announced that the results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy will be presented at the 25th Annual Congress of the European He
Business Wire · 05/14 13:00
Omeros Corporation (OMER) CEO Greg Demopulos on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/12 01:37
Omeros EPS misses by $0.07, misses on revenue
Omeros (NASDAQ:OMER): Q1 Non-GAAP EPS of -$0.41 misses by $0.07; GAAP EPS of -$0.53 misses by $0.19. Revenue of $23.5M (+7.9% Y/Y) misses by $6.71M. Press
seekingalpha · 05/12 01:06
Omeros (OMER) Reports Q1 Loss, Lags Revenue Estimates
Omeros (OMER) delivered earnings and revenue surprises of -2.50% and -23.88%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/11 22:55

Industry

Biotechnology & Medical Research
+0.07%
Pharmaceuticals & Medical Research
-0.77%

Hot Stocks

Symbol
Price
%Change

About OMER

Omeros Corporation is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system. The Company’s drug product OMIDRIA (phenylephrine and ketorolac intraocular solution) is used during cataract surgery or intraocular lens (IOL) replacement. The Company’s clinical-stage development programs are focused on complement-associated thrombotic microangiopathies, complement-mediated glomerulonephropathies, Huntington’s disease and cognitive impairment, and addictive and compulsive disorders. It also offers a diverse group of preclinical programs and platforms that are used to unlock new G protein-coupled receptor (GPCR) drug targets and to generate antibodies.
More

Webull offers kinds of Omeros Corporation stock information, including NASDAQ:OMER real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OMER stock news, and many more online research tools to help you make informed decisions.